CALGB 8251
Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD
N = 361
- Population
- Newly diagnosed advanced Hodgkin's disease, stages IIIA2, IIIB, and IVA or IVB; patients in first relapse after radiation therapy were also eligible. 361 eligible patients.
- Design
- Randomised, multicentre trial of three regimens of primary systemic therapy: MOPP alone for 6 to 8 cycles, MOPP alternating with ABVD for 12 cycles, or ABVD alone for 6 to 8 cycles. Patients were stratified by age, stage, previous radiation, histologic features and performance status. No additional radiation therapy was given. Patients without a complete response, or who relapsed, on MOPP alone or ABVD alone were switched to the opposite regimen.
- Arms
- MOPP (control, n = 123): MOPP (mechlorethamine, vincristine, procarbazine, prednisone) alone for 6 to 8 cycles
- MOPP alternating with ABVD (experimental, n = 123): MOPP alternating with ABVD (doxorubicin, bleomycin, vinblastine, dacarbazine) for 12 cycles
- ABVD (experimental, n = 115): ABVD alone for 6 to 8 cycles
- People
- Canellos GP, senior author Peterson BA
Δ CR rate+16 pointsΔ 60-month FFS+15 pointsΔ 60-month OS+9 points
Show the numbers
| Endpoint | Analysis | MOPP alternating with ABVD / ABVD | MOPP | Effect |
|---|---|---|---|---|
| CR rateEligible patients (361) | finalCanellos 1992 | 83% | 67% | P=0.006P is for the comparison of MOPP with the other two regimens, both of which contained doxorubicin. Across all 361 eligible patients the overall response rate was 93% and the complete response rate 77%. |
| FFSEligible patients (361) | finalCanellos 1992 | 65% at 5 y | 50% at 5 y | Rates at five years. The abstract gives no p-value for failure-free survival; it states that age, stage (III versus IV) and regimen influenced failure-free survival significantly. |
| OSEligible patients (361) | finalCanellos 1992 | 75% at 5 y | 66% at 5 y | P=0.28Rates at five years. P is for the comparison of MOPP with the doxorubicin-containing regimens. |
| Endpoint | Analysis | MOPP alternating with ABVD / ABVD | MOPP | Effect |
|---|---|---|---|---|
| CR rateEligible patients (361) | finalCanellos 1992 | 83% | 67% | P=0.006P is for the comparison of MOPP with the other two regimens, both of which contained doxorubicin. Across all 361 eligible patients the overall response rate was 93% and the complete response rate 77%. |
| FFSEligible patients (361) | finalCanellos 1992 | 65% at 5 y | 50% at 5 y | Rates at five years. The abstract gives no p-value for failure-free survival; it states that age, stage (III versus IV) and regimen influenced failure-free survival significantly. |
| OSEligible patients (361) | finalCanellos 1992 | 75% at 5 y | 66% at 5 y | P=0.28Rates at five years. P is for the comparison of MOPP with the doxorubicin-containing regimens. |